Mounjaro vs Zepbound: The Same Drug, a Different Label and a Very Different Price

Mounjaro and Zepbound are not two competing drugs. They are the same molecule, tirzepatide, made by the same manufacturer, sold under two brand names — and the gap between what people pay for each, cash, is one of the clearest examples on this site of a label driving a price rather than a drug.

Same molecule, same maximum dose, different indication

Per Eli Lilly's FDA prescribing information, Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes¹. Zepbound is indicated for weight reduction in adults with obesity or overweight plus a weight-related comorbidity, and for moderate-to-severe obstructive sleep apnea in adults with obesity² — see Zepbound vs Wegovy for how that second indication compares against semaglutide. Both drugs escalate on the identical schedule — starting at 2.5 mg once weekly for 4 weeks, then increasing in 2.5 mg increments after at least 4 weeks on the current dose — and both cap at the same maximum labeled dose: 15 mg once weekly in adults¹². Same molecule, same ceiling, same escalation rules. The only structural difference the FDA label draws is who it's approved to treat.

Why the price is not the same

Here is where the label starts driving real money. Eli Lilly's self-pay program for cash-pay patients, LillyDirect, discounts Zepbound to roughly $349–$499 a month depending on dose (see the full cash-pay breakdown) — a program built around Zepbound specifically, as the weight-management brand. Mounjaro, priced and marketed as the diabetes brand, does not carry that same consumer discount channel in most cash-pay routes we track: among providers in our roster, NavioMD lists brand Mounjaro at $1,249/month, and Vytora Health lists brand Mounjaro/Zepbound together at $1,399/month near retail — both multiples of Zepbound's LillyDirect self-pay price, for the identical drug at the identical dose (per each provider's published pricing, last reviewed 2026). If you don't have type 2 diabetes and don't need the Mounjaro-specific label, there is essentially no reason to pay the diabetes-brand price for tirzepatide when the weight-management brand is the same molecule at a fraction of the cash cost.

The warning label is identical too

Both drugs carry the same boxed warning: in rodent studies, tirzepatide caused dose-dependent thyroid C-cell tumors, and it is unknown whether this risk translates to humans; both Mounjaro and Zepbound are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2¹². That consistency is exactly what you'd expect from one molecule sold under two names — the safety profile does not change with the label.

What this means for you

If your prescriber writes "Mounjaro" because you have type 2 diabetes, that's the correct, label-matched prescription and often the one your insurance is actually built to cover. If you are cash-pay and being treated for weight rather than diabetes, ask specifically about Zepbound and its LillyDirect self-pay price before accepting a Mounjaro quote at several times the cost for the same drug. Compare both against compounded tirzepatide and run the real annual number — not the first-month price — through our cost calculators. The labels behind this comparison are indexed in our research library. Not medical advice — see our medical disclaimer; which brand and dose is appropriate for you is a decision for your own clinician.